登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
ClinicalTrials.gov 上登记的一项Leber 遗传性视神经病变开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT04912843,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
12 岁 至 75 岁;性别:不限
登记记录的入选字段
The genotype test result is that there is G11778A mutation in ND4 gene, and there are no other primary LHON-associated mutations in the mitochondrial DNA (mtDNA) (ND1[G3460A] or ND6[T14484C]) (confirmed by a CLIA-certified international laboratory)
入选标准第 5 条
A male subject must agree to take contraceptive measures at least 6 months after the treatment visit, see Appendix 5 for details
入选标准第 12 条
A female subject is eligible to participate if she is not pregnant (see Appendix 5), not breastfeeding, and at least one of the following conditions applies:
入选标准第 14 条
Female subjects who are breastfeeding or plan to breastfeed within the first 6 months after the administration of NR082 Injection
排除标准第 16 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04912843,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age at signing of informed consent form In Part 1, the age of the subjects must be ≥ 18 years old and ≤ 75 years old In Part 2, the age of the subjects must be ≥ 12 years old and ≤ 75 years old, and the 6 evaluable subjects must be monitored for at least 6 weeks during the safety run-in phase. If SRC believes that there is no safety issue, the randomized double-blind control study will be initiated Subject Type and Disease Characteristics The clinical manifestation caused by LHON is vision loss, with a visual acuity of ≥ 0.5 LogMAR in BCVA in either eye The genotype test result is that there is G11778A mutation in ND4 gene, and there are no other primary LHON-associated mutations in the mitochondrial DNA (mtDNA) (ND1[G3460A] or ND6[T14484C]) (confirmed by a CLIA-certified international laboratory) The duration of vision loss in the eye with worse visual acuity lasted > 6 months and < 10 years at screening Pupils can be adequately dilated for a comprehensive eye examination and visual acuity test Each eye of the subject must maintain the VA determined by manual visual acuity test (≤ 2.3 LogMAR) as defined in the ocular/vision examination manual (operating manual for optometry and VA examinations) in this study Sign the written informed consent form and willing to comply with the clinical study protocol Sex Male or female Male subjects: A male subject must agree to take contraceptive measures at least 6 months after the treatment visit, see Appendix 5 for details Female subjects: A female subject is eligible to participate if she is not pregnant (see Appendix 5), not breastfeeding, and at least one of the following conditions applies: Written informed consent form must be obtained from the subject or his/her parent/legal guardian (if the subject is under 18 years of age) (Part 2) before any study-related procedures are performed (see Section 10.2) If the subject is legally identified as blind (>1.0 LogMARor decimal acuity meter reading < 0.1), an impartial witness must be present throughout the informed consent process and discussion process.排除标准:Exclusion Criteria:
Any known allergy and/or hypersensitivity to the study drug or its constituents Contraindication to IVT injection in any eye IVT drug delivery to any eye within 30 days prior to the screening visit History of vitrectomy in either eye Narrow anterior chamber angle in any eye contra-indicating pupillary dilation Presence of disorders or diseases of the eye or adnexa, excluding LHON, which may interfere with visual or ocular assessments, including spectral-domain optical coherence tomography (FD-OCT), during the study Presence of known/documented mutations, other than the LHON-related mutation, which are known to cause pathology of the optic nerve, retina or afferent visual system Presence of systemic or ocular/vision diseases, disorders or pathologies, other than LHON, known to cause or be associated with vision loss, or whose associated treatment(s) or therapy(ies) is/are known to cause or be associated with vision loss Presence of optic neuropathy from any cause other than LHON Presence of illness or disease that, in the opinion of the investigator, include symptoms and/or the associated treatments that can alter visual function, for instance cancers or pathology of the CNS, including multiple sclerosis (diagnosis of multiple sclerosis must be based on the 2010 Revisions to the McDonald Criteria) (Polman et al., 2011), and/or diseases or conditions that affect the safety of subjects participating in the study History of recurrent uveitis (idiopathic or immune-related) or active ocular inflammation Participated in another clinical study and receive IP within 90 days prior to the screening visit Any eye has previously received ocular gene therapy Subjects who refused to stop using idebenone Have undergone ocular surgery of clinical relevance (per investigator's assessment) within 90 days prior to the screening visit Female subjects who are breastfeeding or plan to breastfeed within the first 6 months after the administration of NR082 Injection History of drug or alcohol abuse (including heavy smoking, i.e. > 20 cigarettes per day or > 20 pack-years [equivalent to one pack a day for 20 years or 2 packs a day for 10 years]) Subjects with positive human immunodeficiency virus (HIV), syphilis and HCV antibodies are excluded; subjects who have clinically significant active infection requiring treatment as shown by hepatitis B test (defined as positive hepatitis B core antibody [HBcAb] or hepatitis B surface antigen [HBsAg], hepatitis B virus deoxyribonucleic acid (HBV-DNA) >1,000 copies /mL or >lower limit of quantitative detection with the local laboratory method) will be excluded Unable to tolerate or unable or unwilling to comply with all the protocol requirements Subjects from the study site fail to comply with or do not agree to comply with local and institutional guidelines for suspected 2019 novel coronavirus (COVID-19) infection/testing Any other exclusions determined by the investigator
引自 ClinicalTrials.gov, NCT04912843, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04912843,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。